CLOZAPINE Response in Biotype-1
NCT04580134
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
- Schizoaffective Disorder
- Bipolar 1 Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- University of Texas Southwestern Medical Center
- Last updated on ClinicalTrials.gov
- May 11, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Hartford Healthcare · Hartford, CT
Georgia · 1
- University of Georgia · Athens, GA
Illinois · 1
- University of Chicago · Chicago, IL
Massachusetts · 1
- Beth Israel Deaconess Medical Center · Boston, MA
Texas · 1
- UT Southwestern Medical Center · Dallas, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.